A recent study purports to show that FDA warnings about the link between the use of anti-depressants and teen suicide may have led to more suicides. The NYT has an excellent article this morning pointing out that the evidence in the study is far from conclusive.
Assessing the evidence on such issues would be difficult for researchers and medical experts in any case, but the fact that an industry has billions of dollars at stake in pushing a particular position cannot help matters. The pharmaceutical industry has not hesitated to pay large sums to researchers to promote views that support its products. Unfortunately, this article does not mention the perverse incentive created by patent rents on this issue.
There's too much at stake this November for us to quit. As we navigate another presidential election year, thoughtful independent journalism is more important than ever. We're committed to bringing you the latest news on what's really happening across the country this election season, shining a light on the stories corporate media overlooks and keeping the public informed about how power really works in America.
Quality reporting doesn't come for free, and we don't have corporate backers to rely on to fund our work. Everything we do is thanks to our incredible community of readers, who chip in a few dollars at a time to make what we do possible. This month, we're trying to raise $50,000 to help fuel our election coverage, and we've fallen behind on reaching our goal. Any amount you give today will bring us closer to making our reporting possible—and a generous donor has agreed to match all online donations, so your impact will be doubled.
